Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Assembly Biosciences (ASMB) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Assembly Biosciences (ASMB) over the last 9 years, with Q3 2025 value amounting to -$9.2 million.

  • Assembly Biosciences' Net Income towards Common Stockholders rose 433.79% to -$9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.5 million, marking a year-over-year increase of 553.13%. This contributed to the annual value of -$40.2 million for FY2024, which is 3438.13% up from last year.
  • Latest data reveals that Assembly Biosciences reported Net Income towards Common Stockholders of -$9.2 million as of Q3 2025, which was up 433.79% from -$10.2 million recorded in Q2 2025.
  • Assembly Biosciences' Net Income towards Common Stockholders' 5-year high stood at -$8.8 million during Q1 2025, with a 5-year trough of -$62.8 million in Q4 2021.
  • Its 4-year average for Net Income towards Common Stockholders is -$17.5 million, with a median of -$11.2 million in 2024.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 46145.12% in 2021, then skyrocketed by 5210.03% in 2024.
  • Over the past 4 years, Assembly Biosciences' Net Income towards Common Stockholders (Quarter) stood at -$62.8 million in 2021, then skyrocketed by 82.54% to -$11.0 million in 2023, then grew by 5.72% to -$10.3 million in 2024, then increased by 11.02% to -$9.2 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$9.2 million for Q3 2025, versus -$10.2 million for Q2 2025 and -$8.8 million for Q1 2025.